Home>Topics>Companies>Novo Nordisk

Novo Nordisk

  1. All
  2. Commentary
  3. Stock Reports
  4. Video Reports
  5. Fund Reports
  6. ETF Reports
  7. Headlines
  1. Novo Nordisk's Diabetes Pill Shows Promise


    Thu, 26 Jun 2014

    By PLM Investments : Novo Nordisk ( NVO ) is generally recognized as one ..... ongoing oral clinical efforts by Novo that should complete by the end of the year. Novo 's oral diabetes drug development

  2. The Anti-Obesity Space Is Not As Simple As Some Think


    Fri, 20 Jun 2014

    Orexigen, is likely to see its anti-obesity drug approved this Fall. There are other players in the space as well. Novo Nordisk ( NVO ) is seeking an anti-obesity label for its diabetes drug, Victoza, which already has impressive sales, and Zafgen

  3. New Morningstar Analyst Report for MannKind Corp

    Stock Reports

    Wed, 18 Jun 2014

    cancer in former smokers prompted diabetes experts such as Novo Nordisk and Eli Lilly to discontinue their inhaled insulin products ..... insulin class with a negative stigma. Diabetes giants such as Novo and Lilly have pulled their inhaled insulins from development

  4. Moats and Growth Drivers Look Solid for Post-Split Baxter


    Sun, 15 Jun 2014

    much as $1 million, and works only 70% of the time; if ITI fails, patients must move to a bypass therapy, like Novo Nordisk 's NVO NovoSeven or Baxter's Feiba, for life. We think Biogen lacks the long-term data in previously untreated patients

  5. Novo Nordisk diabetes drug appears effective for weight loss -study


    Sat, 14 Jun 2014

    June 14 (Reuters) - Novo Nordisk 's big-selling diabetes drug Victoza appears to be an effective weight loss therapy, data from a late-stage clinical trial presented on Saturday demonstrated.

  6. Novo Nordisk combination diabetes drug effective after 1 yr-study


    Sat, 14 Jun 2014

    June 14 (Reuters) - A Novo Nordisk drug combining its long-acting insulin degludec with its type 2 diabetes treatment Victoza maintained superior blood sugar reduction after one year than either...

  7. New Morningstar Analyst Report for Eli Lilly and Co

    Stock Reports

    Tue, 27 May 2014

    to continue supporting the dividend payments.Lilly has been steadily losing share in the insulin market because of Novo Nordisk 's more effective marketing and the success of its long-acting and rapid-acting insulin analogs.The patent loss

  8. Novo Nordisk's 1Q Hit From Express Scripts Formulary, but Pipeline and Underlying Growth Strong


    Thu, 1 May 2014

    Novo Nordisk reported first-quarter results that were ..... top-line growth rate for 2014. However, Novo is maintaining its operating profit growth ..... fairly valued at recent prices. We think Novo 's strong portfolio of diabetes therapies

  9. New Morningstar Analyst Report for Baxter International Inc.

    Stock Reports

    Mon, 31 Mar 2014

    Biogen Idec and Novo Nordisk are taking aim at Baxter's Advate, and a less-frequent ..... competition for Advate from the likes of Biogen Idec and Novo Nordisk over the next few years could begin to erode the firm's

  10. Makings of a Wide Moat in Diabetes Care


    Fri, 28 Mar 2014

    than growth in more recent years ( Novo Nordisk NVO cites a 14.1% five-year historical ..... AstraZeneca 's AZN Byetta/Bydureon, Novo 's Victoza, Sanofi's Lyxumia ..... insulin players Sanofi, Lilly, and Novo Nordisk . As a result of their wide economic

« Prev12345Next »
Content Partners